Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00837200 · OUTCOME

Study Specific Measure (Response)

Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies · Source last updated 2017-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
16 Weeks

Groups in this outcome

ODD Regimen

Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects. Oncaspar, Doxil, Decadron: Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ODD Regimen12

Reported measurements

Not Evaluable for Response
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
ODD Regimen1Not reportedNot reportedNot reportedNot reported
Stable Disease > 2 months
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
ODD Regimen2Not reportedNot reportedNot reportedNot reported
Progressive Disease
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
ODD Regimen10Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    Not Evaluable for Response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Stable Disease > 2 months
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        10
    title
    Progressive Disease
denoms
  1. counts
    1. group Id
      OG000
      value
      12
    units
    Participants
groups
  1. description
    Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects. Oncaspar, Doxil, Decadron: Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
    id
    OG000
    title
    ODD Regimen
param Type
NUMBER
reporting Status
POSTED
time Frame
16 Weeks
title
Study Specific Measure (Response)
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice